The Supreme Court announced Wednesday that it is taking on a case regarding the Food and Drug Administration’s approval of the chemical abortion pill mifepristone.
Alliance for Hippocratic Medicine, the American Association of Pro-Life Obstetricians and Gynecologists, the American College of Pediatricians and the Christian Medical & Dental Associations filed a lawsuit against the FDA in November 2022, claiming that the FDA had ignored safety protocols to approve the abortion pill mifepristone. The Supreme Court said this week that it would hear the case, one of the first major abortion cases taken up by the court since overturning Roe v. Wade in June 2022, according to an order list.
The Supreme Court in April ruled against the plaintiffs in a 7-2 decision, with Justices Samuel Alito and Clarence Thomas dissenting, regarding a request for a temporary stay of the FDA’s ability to administer the drug. The fifth U.S. Circuit Court of Appeals, however, ruled in August that the FDA must reverse changes it made allowing the pill to be mailed online and dispensed by pharmacies without a doctor’s prescription, according to Politico.
The FDA appealed the decision to the Supreme Court in September, according to Axios. The court noted in its decision Wednesday that oral arguments on the case would be limited to one hour.
The FDA “does not comment on possible, pending or ongoing litigation,” it told the Daily Caller News Foundation.
All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact [email protected].
